Mr Phil Willis MP, Chairman of the House of Commons’ Science and Technology Select Committee, who unveiled the plaque said, “It is a huge privilege to officially open the new ‘Minerva’ research facility which offers emerging biotech companies state of the art facilities to bring excellent science to the market. This facility is a superb example of how government funding can stimulate knowledge transfer by sponsoring direct links between academia and industry and stimulating wealth creation in the regions.”
Minerva is the first of three BioDevelopment buildings, offering flexible laboratory and office accommodation, which are anticipated will stimulate and facilitate the knowledge transfer process from research to commercial exploitation on the campus. Dr David Hardman, CEO of BBT said, “This BioDevelopment building is the latest development in our Babraham Research Campus strategy to integrate world class science with innovative bioventures to exploit new technologies relating to human healthcare. This building enables companies to expand into new facilities on flexible terms, a unique proposition in the region. The campus has been home to over 40 of the region’s biotechnology companies since it opened in 1998 and BBT will start a new Bioincubator building in September. The continued success emphasises the role our knowledge-based campus can play in promoting biosciences for regional development.”
Cambridge Biotechnology Ltd, a drug-discovery research company developing novel therapeutics for the treatment of pain, inflammation and obesity, is one of the four companies residing in Minerva. Dr Peter Richardson, Managing Director of CBT said, "Moving to new facilities at Babraham represents a major new phase in the growth of CBT. The new laboratories will provide CBT's drug discovery teams with excellent working conditions and will ensure optimal efficiency and safety for all its research staff. A location on the Babraham Research Campus also benefits from the proximity of a host of innovative biotech companies and prestigious academic groups which provides an optimal environment for a company such as CBT to thrive."
Also in Minerva are NovaThera Ltd, a spin-out from Imperial College London that is pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering, and Stem Cell Sciences plc, an international company with centres in the United Kingdom, Australia, Japan and the USA. Active in the stem cell research field since 1994, the company is principally focused on expertise to grow, differentiate, select and purify stem cells. Cyclacel, the Dundee-based biopharmaceutical company dedicated to the discovery, development and commercialisation of novel, mechanism-targeted drugs to treat human cancers, moved into Minerva from the Bioincubator facilities earlier this year.
Claire Cockcroft | alfa
Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute
Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy